USA's BARDA expands Summit's ridinilazole award

23 January 2020

Anglo-American antibiotics developer Summit Therapeutics’ (AIM: SUMM) shares shot up 13.3% to 23.80 pence today, after it announced that the US Biomedical Advanced Research and Development Authority (BARDA) has expanded its award for the clinical and regulatory development of Summit’s investigational precision antibiotic ridinilazole for the treatment of Clostridium difficile infection (CDI) by $8.8 million.

The additional funding is being provided to support a new clinical trial in adolescent patients and brings the total value of the award to up to $72.5 million. The adolescent clinical trial is expected to support a New Drug Application for ridinilazole and also form part of a package of work with the potential to provide an additional six months market exclusivity for ridinilazole in the USA and Europe.

“BARDA’s continued support for ridinilazole is instrumental in helping to bring this potential CDI treatment option to patients, whose current treatment options fail to sustain cures for one third of the population,” said chief executive Glyn Edwards.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK